We are pleased to announce that NeoPhore recently achieved all of its investment related scientific milestones, enabling the contingent second completion funding of £9.4m to be issued from the previously reported series B investment round. The financing will be used to further progress NeoPhore’s lead compounds from drug discovery programs targeting the DNA mismatch repair pathway.
02.02.2022
NeoPhore achieves scientific milestones
More news
18.02.2022
St George’s expands successful collaboration in pursuit of new, first-in-class cancer therapies
St George’s, University of London and NeoPhore today announce the expansion of their research partnership after a successful collaboration i…
11.10.2021
Additional Series B funding announcement
We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli…
31.08.2021
NeoPhore appoints Stephen Over as Chief Financial Officer
We are delighted to announce the appointment of Stephen Over as the Company's Chief Financial Officer and new member of the Executive team. Stephen…